BIO5192 hydrate|西域试剂

BIO5192 hydrate,99.78%

产品编号：Bellancom-107589A| 分子式：C₃₈H₄₆C_l2N₆O₈S.1/2H₂O| 分子量：826.79

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-107589A		￥2200.00	杭州北京（现货）
Bellancom-107589A		￥3500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

BIO5192 hydrate

产品介绍

BIO5192 hydrate 是一种选择性强的整合素 α4β1 (VLA-4) 抑制剂 (K_d<10 pM)。BIO5192 hydrate 选择性地与 α4β1 (IC₅₀=1.8 nM) 结合，选择性高过其他一系列整合素。BIO5192 hydrate 导致小鼠造血干细胞和祖细胞 (HSPCs) 的动员比基础水平增加 30 倍。

生物活性

BIO5192 hydrate is a selective and potent integrin α4β1 (VLA-4) inhibitor (K_d<10 pM). BIO5192 hydrate selectively binds to α4β1 (IC₅₀=1.8 nM) over a range of other integrins. BIO5192 hydrate results in a 30-fold increase in mobilization of murine hematopoietic stem and progenitors (HSPCs) over basal levels.

体外研究

体内研究

The combination of BIO5192 hydrate (1 mg/kg; i.v.) and Plerixafor (5 mg/kg; s.c.) exert an additive effect on progenitor mobilization.
BIO5192 hydrate (30 mg/kg; s.c; bid; during days 5 through 14) delays paralysis associated with EAE (experimental autoimmune encephalomyelitis).
BIO5192 hydrate (1 mg/kg, i.v.) shows the terminal half-life is 1.1 hours. BIO5192 hydrate (3, 10, and 30 mg/kg; s.c.) shows half-lives of 1.7, 2.7, and 4.7 hours, respectively. The blood plasma curves show that the AUC for the s.c. route of administration increased about 2.5-fold from 5,460 h*ng/ml for the 3 mg/kg dose to 14,175 h*ng/ml for the 30 mg/kg.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6J x 129Sv/J F1 mice
Dosage:	1 mg/kg (with Plerixafor: 5 mg/kg)
Administration:	I.v.
Result:	Exerted an additive effect on progenitor mobilization.

Animal Model:	Healthy female Lewis rats weighing 150g
Dosage:	30 mg/kg
Administration:	S.c; bid; during days 5 through 14
Result:	Showed a 3-day delay in onset of disease.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6J x 129Sv/J F1 mice
Dosage:	1 mg/kg (with Plerixafor: 5 mg/kg)
Administration:	I.v.
Result:	Exerted an additive effect on progenitor mobilization.

Animal Model:	Healthy female Lewis rats weighing 150g
Dosage:	30 mg/kg
Administration:	S.c; bid; during days 5 through 14
Result:	Showed a 3-day delay in onset of disease.

性状

Solid

溶解性数据

In Vitro:

DMSO : ≥ 100 mg/mL (120.95 mM)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.2095 mL	6.0475 mL	12.0950 mL
5 mM	0.2419 mL	1.2095 mL	2.4190 mL
10 mM	0.1209 mL	0.6047 mL	1.2095 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (3.02 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (3.02 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (3.02 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (3.02 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。